title: Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
abstract: Anticancer vaccine strategies can now target intracellular antigens that are involved in the process of malignant transformation, such as oncogene products or mutated tumor suppressor genes. Fragments of these antigens, generally 8-10 amino acids in length and complexed with MHC class I molecules, can be recognized by CD8+ T lymphocytes (TCD8+). To explore the possibility of using a genetically encoded, minimally sized fragment of an intracellular antigen as an immunogen, we constructed a recombinant vaccinia virus encoding an 8-residue peptide derived from chicken ovalbumin that is known to associate with the mouse H-2Kb molecule. Compared to standard methods of immunization, recombinant molecule. Compared to standard methods of immunization, recombinant vaccinia virus expressing the minimal determinant as well as full length ovalbumin were the only approaches that elicited specific primary lytic responses in C57BL/6 mice against E.G7OVA, a transfectant of the murine thymoma EL4 containing the ovalbumin gene. Stimulating these effectors in vitro with OVA257-264 peptide induced H-2Kb-restricted TCD8+ that not only lysed but also specifically secreted IFN-gamma in response to an antigen. Furthermore, when transferred adoptively, these anti-OVA257-264 TCD8+ cells significantly reduced the growth of established ovalbumin-transfected tumors in a pulmonary metastasis model system. Synthetic transfected tumors in a pulmonary metastasis model system. Synthetic oligonucleotides encoding minimal antigenic determinants within expression constructs may be a useful approach for treatment of neoplastic disease, thus avoiding the potential hazards of immunizing with full-length cDNAs that are potentially oncogenic.
authors.affiliation: Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: McCabe
authors.forename: K R
authors.initials: KR
authors.lastname: Irvine
authors.forename: M I
authors.initials: MI
authors.lastname: Nishimura
authors.forename: J C
authors.initials: JC
authors.lastname: Yang
authors.forename: P J
authors.initials: PJ
authors.lastname: Spiess
authors.forename: E P
authors.initials: EP
authors.lastname: Shulman
authors.forename: S A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: N P
authors.initials: NP
authors.lastname: Restifo
mesh_terms: D000818:Animals; D001483:Base Sequence; D002645:Chickens; D003602:Cytotoxicity, Immunologic; D000939:Epitopes / Q000096:biosynthesis; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides; D010047:Ovalbumin / Q000096:biosynthesis / Q000276:immunology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D013945:Thymoma / Q000276:immunology* / Q000628:therapy; D013953:Thymus Neoplasms / Q000276:immunology* / Q000628:therapy; D014407:Tumor Cells, Cultured; D014614:Vaccines, Synthetic / Q000627:therapeutic use*; D014616:Vaccinia virus
chemical_list: D000939:Epitopes; D009838:Oligodeoxyribonucleotides; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D010047:Ovalbumin